Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Taking the Long View: Imatinib Success Story Stands the Test of Time

May 22nd 2012

The demonstrated impact of imatinib mesylate on outcomes for patients with CML shifted the oncology paradigm to an intensive search for relevant molecular target.

May 2012: Trials in Progress

May 14th 2012

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Dr. Ansell on Waldenström Macroglobulinemia Treatments

May 11th 2012

Dr. Stephen Ansell, from the Mayo Clinic, on Treating Patients With Waldenström Macroglobulinemia

Meeting the Challenges in Treating Lymphoma: A Conversation With Andrew D. Zelenetz, MD, PhD

May 8th 2012

Discussion with Andrew D. Zelenetz, MD, PhD, on a number of new therapies and interesting challenges regarding the treatment of patients with both Hodgkin and non- Hodgkin lymphoma.

Dr. Erba Discusses Molecular Monitoring for CML

May 8th 2012

Dr. Harry Erba, from University of Michigan Health System, Discusses Molecular Monitoring for CML

Michael Eckenfels on Bortezomib Delivery Route Changes

May 5th 2012

Michael Eckenfels, RN, OCN, from MD Anderson Cancer Center, on Changes to the Bortezomib Delivery Route.

Emerging Markers Point to Future Strategies in CLL: An Interview With William G. Wierda, MD, PhD

April 27th 2012

William G. Wierda, MD, PhD, discussed the management of chronic lymphocytic leukemia at the 16th Annual International Congress on Hematologic Malignancies.

Dr. Zelenetz Discusses Treatment Options for DLBCL

April 26th 2012

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses Treatment Options for DLBCL

Novel Treatments for Chronic Lymphocytic Leukemia

April 20th 2012

Results of recent trials investigating novel therapies for chronic lymphocytic leukemia were discussed at the 16th Annual International Congress on Hematologic Malignancies.

Beyond R-CHOP-21: What's New in Diffuse Large B-Cell Lymphoma

April 19th 2012

The prognosis for a significant fraction of DLBCL patients that relapse while receiving the current standard treatment of R-CHOP-21 remains poor.

April 2012: Trials in Progress

April 17th 2012

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Dr. Dunleavy Discusses Treatment Options for PMBL

April 16th 2012

Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses Treatment Options for Primary Mediastinal B Cell Lymphoma

How Fellows Can Add Value to Their Internal Medicine Residency Program

April 15th 2012

There are many ideas that if followed will not just help you to "do your time" during fellowship, but contribute to the internal medicine residency program.

(Never) A Typical Day in the Life of a Pediatric Hematologist/Oncologist

April 15th 2012

There is no such thing as a typical day. Our days are punctuated by the unexpected and our field is so diverse that we often change what we do over the course of our careers. Time alters us and our field.

Elotuzumab Responses High in Multiple Myeloma Study

April 12th 2012

Elotuzumab demonstrated notable response rates as combination therapy in a phase II study of patients with relapsed or refractory multiple myeloma.

Dr. Zelenetz Discusses DLBCL Targeted Therapies

March 29th 2012

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, on Targeted Therapies for Diffuse Large B-cell Lymphoma

Dr. Erba Discusses the Frontline Treatment of CML

March 28th 2012

Dr. Harry Erba, from the University of Michigan Health System, Discusses the Frontline Treatment of CML

Dr. Dunleavy Discusses ABC DLBCL Research

March 23rd 2012

Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses ABC DLBCL Research

Lenalidomide Improves Outcomes in Asymptomatic High-Risk Smoldering and Newly Diagnosed Myeloma

March 23rd 2012

Continuous treatment with lenalidomide given early prolonged the time to progression, compared with no treatment in patients with high-risk, asymptomatic, smoldering, multiple myeloma.

ODAC Endorses Drug for Rare Leukemia

March 21st 2012

ODAC voted 7-4 (2 abstentions) in support of vincristine sulfate liposomes injection to treat patients with Ph-negative ALL.

NEXT PAGE
PREVIOUS PAGE